REGN/MRK: Takeaways From Recent Retina Expert Call

We recently hosted a call with Dr. Carl Regillo (Wills Eye Hospital/Thomas Jefferson University) to discuss his views on the commercial and evolving clinical landscapes for retinal diseases, including 1) how he currently uses Eylea HD and Vabysmo and the impact recent data from Kodiak will have on these products, 2) how recent Eylea HD label expansions have influenced his use and 3) his impressions of MRK's remigromig/MK-8748 programs. Overall, he has a favorable view of REGN's Eylea HD, noting that it is currently the fastest-growing product in his practice among available therapies but expects KOD's Zenkuda would have some modest impact on the franchise over time (with payer hurdles likely limiting broad uptake). Dr. Regillo further sees potential for MRK's pipeline, with remigromig having an oppty in those that do not respond well to current therapies. As we think about the space more broadly, we expect REGN's Eylea HD will continue its steady ramp as the RVO and Q4W dosing label en